

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name ☒ Organization/Lobbying Firm ☐ Self Employed Individual

Williams & Jensen, PLLC.

2. Address ☐ Check if different than previously reported

Address1 1155 Twenty-First Street, N.W. Address2 Suite 300  
City Washington State DC Zip Code 20036 - Country USA

3. Principal place of business (if different than line 2)

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ - Country \_\_\_\_\_

4a. Contact Name

b. Telephone Number c. E-mail

5. Senate ID#

Elizabeth Chapman

☐ International Number

(202) 659-8201

erchapman@wms-jen.com

41454-924

7. Client Name ☐ Self ☐ Check if client is a state or local government or instrumentality

6. House ID#

ASTRAZENECA PHARMACEUTICALS GROUP

307710057

TYPE OF REPORT 8. Year 2009 Q1 (1/1 - 3/31) ☒ Q2 (4/1 - 6/30) ☐ Q3 (7/1-9/30) ☐ Q4 (10/1 - 12/31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ Termination Date \_\_\_\_\_ 11. No Lobbying Issue Activity ☐

### INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13

#### 12. Lobbying

INCOME relating to lobbying activities for this reporting period was:

Less than \$5,000 ☐

\$5,000 or more ☒ \$ \$ 100,000.00

Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

#### 13. Organizations

EXPENSE relating to lobbying activities for this reporting period were:

Less than \$5,000 ☐

\$5,000 or more ☐ \$ \_\_\_\_\_

14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.

☐ Method A. Reporting amounts using LDA definitions only

☐ Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

☐ Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature Filed Electronically Date 04/20/2009

Printed Name and Title George Olsen

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code

MMM

MEDICARE/MEDICAID

(one per page)

16. Specific lobbying issues

Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; and

17. House(s) of Congress and Federal agencies

☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
George	Olsen			<input type="checkbox"/>
Karina	Lynch		Staff, Senate Special Committee on Aging	<input type="checkbox"/>
Karina	Lynch continued		Staff, Senate Committee on Government Affairs	<input type="checkbox"/>
J. Steven	Hart			<input type="checkbox"/>
Jenny	DiJames		LA and LD, Rep. Bud Cramer	<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Printed Name and Title

George Olsen

Medicare drug price negotiation, payment, and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Prescription Drug Gap Reduction Act of 2009.

Printed Name and Title George Olsen

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code

HCR

HEALTH ISSUES

(one per page)

16. Specific lobbying issues

Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
George	Olsen			<input type="checkbox"/>
Karina	Lynch		Staff, Senate Special Committee on Aging	<input type="checkbox"/>
Karina	Lynch continued		Staff, Senate Committee on Government Affairs	<input type="checkbox"/>
Susan	Hirschmann		COS, Rep.Van Hilleary & Majority Whip	<input checked="" type="checkbox"/>
Jenny	DiJames		LA and LD, Rep. Bud Cramer	<input checked="" type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title George Olsen

Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act;

Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009;

Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act;

Health information technology including H.R. 1, the American Recovery and Reinvestment Act;

Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;

Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act;

Health care reform;

Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009;

Prescription drug advertising;

Federal preemption for prescription drugs; and

Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code

TAX

TAXATION/INTERNAL REVENUE CODE

(one per page)

16. Specific lobbying issues

Tax issues affecting the pharmaceutical industry.

17. House(s) of Congress and Federal agencies

☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
George	Olsen			<input type="checkbox"/>
Christopher	Hatcher		Staff Asst.; Special Asst.; & Leg. Manger, Treasury.	<input type="checkbox"/>
Christopher	Hatcher continued		LD, Rep. Scott McInnis	<input type="checkbox"/>
Joel	Oswald		Prof.Staff,, Senate Banking Comte; LA,Sen.Enzi.	<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Printed Name and Title

George Olsen